BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977 [PMID: 27833388 DOI: 10.3748/wjg.v22.i40.8967] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Ohara T, Tomono Y, Boyi X, Yingfu S, Omori K, Matsukawa A. A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines. Oncotarget 2018;9:32751-60. [PMID: 30214682 DOI: 10.18632/oncotarget.25973] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
2 Buschhaus JM, Rajendran S, Humphries BA, Cutter AC, Muñiz AJ, Ciavattone NG, Buschhaus AM, Cañeque T, Nwosu ZC, Sahoo D, Bevoor AS, Shah YM, Lyssiotis CA, Ghosh P, Wicha MS, Rodriguez R, Luker GD. Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer. Oncogene 2022. [PMID: 35732800 DOI: 10.1038/s41388-022-02385-9] [Reference Citation Analysis]
3 Khan A, Singh P, Srivastava A. Iron: Key player in cancer and cell cycle? J Trace Elem Med Biol 2020;62:126582. [PMID: 32673942 DOI: 10.1016/j.jtemb.2020.126582] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Steinbrueck A, Sedgwick AC, Han HH, Zhao MY, Sen S, Huang DY, Zang Y, Li J, He XP, Sessler JL. In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics. Chem Commun (Camb) 2021;57:5678-81. [PMID: 33977921 DOI: 10.1039/d0cc08156f] [Reference Citation Analysis]
5 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
6 Hugo MM, Banerjee IA. Development of new amphiphilic bio-organic assemblies for potential applications in iron-binding and targeting tumor cells. Soft Materials 2019;17:57-76. [DOI: 10.1080/1539445x.2018.1548357] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Li B, Liao Z, Mo Y, Zhao W, Zhou X, Xiao X, Cui W, Feng G, Zhong S, Liang Y, Du C, Huang G, Li P, Xiao X, Zhou X, Wang R, Zhang Z. Inactivation of 3-hydroxybutyrate dehydrogenase type 2 promotes proliferation and metastasis of nasopharyngeal carcinoma by iron retention. Br J Cancer 2020;122:102-10. [PMID: 31819181 DOI: 10.1038/s41416-019-0638-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Wang H, Lin D, Yu Q, Li Z, Lenahan C, Dong Y, Wei Q, Shao A. A Promising Future of Ferroptosis in Tumor Therapy. Front Cell Dev Biol 2021;9:629150. [PMID: 34178977 DOI: 10.3389/fcell.2021.629150] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Hsu MY, Mina E, Roetto A, Porporato PE. Iron: An Essential Element of Cancer Metabolism. Cells 2020;9:E2591. [PMID: 33287315 DOI: 10.3390/cells9122591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Joachim JH, Mehta KJ. Hepcidin in hepatocellular carcinoma. Br J Cancer 2022. [PMID: 35264787 DOI: 10.1038/s41416-022-01753-2] [Reference Citation Analysis]
11 Zhou N, Cui Y, Zhu R, Kuang Y, Ma W, Hou J, Zhu Y, Chen S, Xu X, Tan K, Cao P, Duan X, Fan Y. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo. Gynecologic Oncology 2022. [DOI: 10.1016/j.ygyno.2022.05.006] [Reference Citation Analysis]
12 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Szlasa W, Gachowska M, Kiszka K, Rakoczy K, Kiełbik A, Wala K, Puchała J, Chorążykiewicz K, Saczko J, Kulbacka J. Iron chelates in the anticancer therapy. Chem Pap . [DOI: 10.1007/s11696-021-02001-2] [Reference Citation Analysis]
14 Greene CJ, Attwood K, Sharma NJ, Gross KW, Smith GJ, Xu B, Kauffman EC. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget 2017;8:107052-75. [PMID: 29291011 DOI: 10.18632/oncotarget.22323] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
15 Shinoda S, Kaino S, Amano S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Oncotarget 2018;9:28434-44. [PMID: 29983871 DOI: 10.18632/oncotarget.25421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
16 Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. BMC Cancer 2020;20:681. [PMID: 32698792 DOI: 10.1186/s12885-020-07167-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Ibrahim O, O'Sullivan J. Iron chelators in cancer therapy. Biometals 2020;33:201-15. [PMID: 32757166 DOI: 10.1007/s10534-020-00243-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Gray JP, Suhali-amacher N, Ray SD. Metals and Metal Antagonists. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2017. pp. 197-208. [DOI: 10.1016/bs.seda.2017.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Makita Y, Murata S, Katou Y, Kikuchi K, Uejima H, Teratani M, Hoashi Y, Kenjo E, Matsumoto S, Nogami M, Otake K, Kawamata Y. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma. Biochem Biophys Res Commun 2017;493:800-6. [PMID: 28843857 DOI: 10.1016/j.bbrc.2017.08.088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
20 Huang H, Qiu Y, Huang G, Zhou X, Zhou X, Luo W. Value of Ferritin Heavy Chain (FTH1) Expression in Diagnosis and Prognosis of Renal Cell Carcinoma. Med Sci Monit 2019;25:3700-15. [PMID: 31104064 DOI: 10.12659/MSM.914162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
21 Qin J, Zhou C, Zhu M, Shi S, Zhang L, Zhao Y, Li C, Wang Y, Wang Y. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinoma. Photodiagnosis and Photodynamic Therapy 2020;31:101907. [DOI: 10.1016/j.pdpdt.2020.101907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Yang Y, Xu Y, Su A, Yang D, Zhang X. Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism. Med Sci Monit 2018;24:6735-41. [PMID: 30246777 DOI: 10.12659/MSM.910325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 You H, Wang D, Wei L, Chen J, Li H, Liu Y, Hou Y. Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1α, Wnt/β-Catenin, and p38MAPK/ERK Pathways. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/8281267] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Hui Y, Tang T, Wang J, Zhao H, Yang HY, Xi J, Zhang B, Fang J, Gao K, Wu Y. Fusaricide is a Novel Iron Chelator that Induces Apoptosis through Activating Caspase-3. J Nat Prod 2021;84:2094-103. [PMID: 34292737 DOI: 10.1021/acs.jnatprod.0c01322] [Reference Citation Analysis]
25 Greene CJ, Sharma NJ, Fiorica PN, Forrester E, Smith GJ, Gross KW, Kauffman EC. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Free Radical Biology and Medicine 2019;133:295-309. [DOI: 10.1016/j.freeradbiomed.2018.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
26 Theerasilp M, Chalermpanapun P, Ponlamuangdee K, Sukvanitvichai D, Nasongkla N. Imidazole-modified deferasirox encapsulated polymeric micelles as pH-responsive iron-chelating nanocarrier for cancer chemotherapy. RSC Adv 2017;7:11158-69. [DOI: 10.1039/c6ra26669j] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
27 Pita-grisanti V, Chasser K, Sobol T, Cruz-monserrate Z. Understanding the Potential and Risk of Bacterial Siderophores in Cancer. Front Oncol 2022;12:867271. [DOI: 10.3389/fonc.2022.867271] [Reference Citation Analysis]
28 Sodagar Taleghani A, Ebrahimnejad P, Heydarinasab A, Akbarzadeh A. Adsorption and controlled release of iron-chelating drug from the amino-terminated PAMAM/ordered mesoporous silica hybrid materials. Journal of Drug Delivery Science and Technology 2020;56:101579. [DOI: 10.1016/j.jddst.2020.101579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Brown RAM, Richardson KL, Kabir TD, Trinder D, Ganss R, Leedman PJ. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology. Front Oncol 2020;10:476. [PMID: 32328462 DOI: 10.3389/fonc.2020.00476] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]